Some TB vaccines, such as BCG or the CysVac2/Advax candidate, have been observed to be more protective after intranasal or intrapulmonary administration, a quality attributed to local IL-17 production and the establishment of TRM (37, 119). Here, IL17A is linked to tuberculosis.